Fig. 1 · Structure

Documents & Downloads

Ceftiofur hydrochloride

Cat. No. A10191 CAS 103980-44-5
Ceftiofur is an antibiotic of the cephalosporin type (third generation)

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Ceftiofur hydrochloride Research Summary

This section summarizes 2 in vivo studies of Ceftiofur hydrochloride from 2 published references.

Ceftiofur hydrochloride In Vivo Studies

In a randomized crossover study in 24 healthy pigs, two 5% ceftiofur hydrochloride suspensions produced similar plasma exposure after a single 5 mg/kg intramuscular dose. The assay measured ceftiofur and desfuroylceftiofur-related metabolites, rather than parent drug alone. These findings apply to the tested formulations. [1]

In five healthy water buffalo, two ceftiofur hydrochloride suspensions given intramuscularly at 2.2 mg/kg differed in peak concentration and mean residence time, while total exposure did not differ significantly. This formulation-dependent result limits generalization of pharmacokinetics across hydrochloride preparations. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Plasma disposition of two hydrochloride suspensions in healthy pigs

Animal study · 24 healthy Landrace pigs; 12 male and 12 female; randomized two-period, two-treatment crossover with a 7-day washout. [1]

The two suspensions produced similar plasma exposure in this crossover experiment. HPLC quantified ceftiofur and DFC-related metabolites after conversion to DFC. All animals remained healthy and no adverse reactions were observed; this single-dose observation is not a general safety assessment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Plasma ceftiofur and DFC-related metabolitesCmax Test: 34.6 ± 5.5 µg/ml; reference: 36.1 ± 6.2 µg/ml (mean ± SD, n=24).[1]
Plasma ceftiofur and DFC-related metabolitesAUC0-t Test: 376.7 ± 75.3 µg·hr/ml; reference: 390.5 ± 78.6 µg·hr/ml (mean ± SD, n=24).[1]
Relative exposure of test versus reference suspensionRelative bioavailability 96.47 ± 10.92% (mean ± SD, n=24).[1]
Between-formulation comparison of Cmax, AUC0-t and AUC0-∞Statistical comparison No statistically significant differences reported.[1]

Conditions shared by the study groups

Route
Intramuscular
Frequency
Once per period
Treatment course
One dose
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Test suspension
5 mg/kg body weight
Active reference suspension in the same pigs in the other periodCmax 34.6 ± 5.5 µg/ml; AUC0-t 376.7 ± 75.3 µg·hr/ml (mean ± SD, n=24).[1]
Reference suspension
5 mg/kg body weight
Test suspension in the same pigs in the other periodCmax 36.1 ± 6.2 µg/ml; AUC0-t 390.5 ± 78.6 µg·hr/ml (mean ± SD, n=24).[1]
Test suspension
Model: Healthy Landrace pigs in crossover
Vehicle: Saifukang 5% CEF sterile suspension
Reference suspension
Model: Healthy Landrace pigs in crossover
Vehicle: Excenel RTU 5% CEF sterile suspension
Methods and source locations

Compound reported in the paper: Ceftiofur hydrochloride; Compound label in the paper: Saifukang 5% CEF (test) and Excenel RTU 5% CEF (reference)

Disposition of the named suspensions in pigs; neither an assay IC50 nor evidence of Adooq lot performance.

Materials and Methods; Results Tables 1–4; Figure 1/caption

Plasma ceftiofur and DFC-related metabolites: HPLC following conversion to DFC; observed maximum concentrations. — Table 2; Analysis of plasma CEF and DFC-related metabolites concentrations

Plasma ceftiofur and DFC-related metabolites: Linear trapezoidal calculation. — Table 2; Pharmacokinetic and bioequivalence analysis

Relative exposure of test versus reference suspension: Based on AUC0-t; relative, not absolute, bioavailability. — Table 2; Bioequivalence analysis

Between-formulation comparison of Cmax, AUC0-t and AUC0-∞: Log-transformed parameter comparison by ANOVA. — Bioequivalence analysis; Table 3

Test suspension · Drugs and reagents; Bioequivalence study design; Table 2

Reference suspension · Drugs and reagents; Bioequivalence study design; Table 2

Formulation-dependent disposition in healthy adult water buffalo

Animal study · Five healthy adult Murrah-crossbred water buffalo (3 male, 2 nonlactating female); fixed sequence CEF1, CEF2, CEF3, with 20-day washouts. [2]

CEF1 had longer mean residence time and lower peak concentration than CEF2, whereas AUC0–∞ and bioavailability did not differ significantly. The measured plasma endpoint was based on derivatization to desfuroylceftiofur acetamide. The sodium IV arm supplied a disposition comparator; it was not a hydrochloride IV treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Plasma ceftiofur-related exposure after hydrochloride suspensionsMRT0–∞ CEF1: 22.63 ± 2.81 h; CEF2: 13.99 ± 2.86 h (mean ± SD, n=5); P = 0.01.[2]
Plasma ceftiofur-related exposure after hydrochloride suspensionsCmax CEF1: 3.782 ± 0.855 µg/mL; CEF2: 6.208 ± 1.420 µg/mL (mean ± SD, n=5); P < 0.05.[2]
Plasma ceftiofur-related exposure after hydrochloride suspensionsAUC0–∞ CEF1: 65.88 ± 18.41 µg·h/mL; CEF2: 64.05 ± 4.32 µg·h/mL (mean ± SD, n=5); no significant difference reported.[2]

Conditions shared by the study groups

Frequency
Once
Treatment course
One dose
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
CEF1 hydrochloride suspension
2.2 mg/kg
CEF2 in the same animals; CEF3 sodium IV comparatorMRT0–∞ 22.63 ± 2.81 h; Cmax 3.782 ± 0.855 µg/mL (mean ± SD).[2]
CEF2 hydrochloride suspension
2.2 mg/kg
CEF1 in the same animals; CEF3 sodium IV comparatorMRT0–∞ 13.99 ± 2.86 h; Cmax 6.208 ± 1.420 µg/mL (mean ± SD).[2]
CEF3 sodium comparator
2.2 mg/kg
Hydrochloride suspensions in the same animals in preceding periodsIV comparator for disposition and bioavailability calculations; no equivalence of salt formulations inferred.[2]
CEF1 hydrochloride suspension
Model: Five healthy adult water buffalo
Route: Intramuscular
Vehicle: 5% ceftiofur hydrochloride suspension, Guangxi Beidouxing Animal Drugs Co; oil-based
CEF2 hydrochloride suspension
Model: Five healthy adult water buffalo
Route: Intramuscular
Vehicle: Excenel 5% ceftiofur hydrochloride suspension, Pfizer
CEF3 sodium comparator
Model: Five healthy adult water buffalo
Route: Intravenous
Vehicle: Excenel ceftiofur sodium powder dissolved in sterile water
Methods and source locations

Compound reported in the paper: Ceftiofur hydrochloride; Compound label in the paper: CEF1 and CEF2 hydrochloride suspensions; CEF3 sodium IV comparator

Named hydrochloride formulations in healthy buffalo; quantitative PK is not transferable to catalog powder or other species.

Experimental design through Statistical analysis; Results Pharmacokinetics, Tables 2–3; footnotes c–e

Plasma ceftiofur-related exposure after hydrochloride suspensions: Noncompartmental analysis. — Table 3, MRT0–∞ row and † footnote

Plasma ceftiofur-related exposure after hydrochloride suspensions: HPLC after derivatization to desfuroylceftiofur acetamide; individual maxima summarized. — Table 3, Cmax row and * footnote; Analysis of plasma ceftiofur concentrations

Plasma ceftiofur-related exposure after hydrochloride suspensions: Noncompartmental analysis. — Table 3, AUC0–∞ row; Results, Pharmacokinetics

CEF1 hydrochloride suspension · Experimental design; Table 3; Discussion; footnote c

CEF2 hydrochloride suspension · Experimental design; Table 3; footnote d

CEF3 sodium comparator · Experimental design; Pharmacokinetic analysis; footnote e

Specifications

Manufacturer Adooq Bioscience
CAS Number 103980-44-5
Formula C19H18ClN5O7S3
Molecular Weight 560.02
SMILES
CO/N=C(/C1=CSC(=N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSC(=O)C4=CC=CO4)C(=O)O.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 93 mg/mL (166.06 mM)
Water Insoluble
Ethanol 20 mg/mL (35.71 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Ceftiofur hydrochloride Research References

  1. [1] Jincheng Xiong, Qianqian Zhu, Zhixin Lei, et al. Bioequivalence evaluation of two 5% ceftiofur hydrochloride sterile suspension in pigs Journal of Veterinary Medical Science (2018). PMID: 30381675 DOI: 10.1292/jvms.18-0470 Source material
  2. [2] Haiying Nie, Xin Feng, Jianbo Peng, et al. Comparative pharmacokinetics of ceftiofur hydrochloride and ceftiofur sodium after administration to water buffalo (Bubalus bubalis) American Journal of Veterinary Research (2016). PMID: 27227504 DOI: 10.2460/ajvr.77.6.646 Source material

Added to your cart

View Cart Checkout
Loading...